CCO Treatment Updates
Bone Health and Skeletal Complications in Cancer: Insights Into Pathogenesis, Advances in Management
Breast Cancer and Bone Health: New and Emerging Treatment Options |
Module 1 of 4 |
- Robert E. Coleman, MD, FRCP
|
|
|
Robert E. Coleman, MD, FRCP, reviews the current understanding of bone loss associated with breast cancer and its treatment and recent clinical trial data on emerging therapies to prevent bone destruction in breast cancer patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the effect of aromatase inhibitors on bone health in women with breast cancer
- Explain current thinking regarding management of bone loss in patients receiving treatment for breast cancer
- Discuss recent clinical trial data on bisphosphonates used to mitigate metastatic bone disease in breast cancer patients
- Cite the potential role of bone turnover markers as prognostic indicators in patients with breast cancer
- Describe ongoing clinical research into therapies that target the receptor activator of nuclear factor kappa B (RANK)/RANK ligand pathway in initiation of osteoclastic bone resportion with the aim of preventing bone loss and skeletal-related events in patients with breast cancer
Abstract
|
Optimizing Bone Health in Patients With Prostate Cancer |
Module 2 of 4 |
- Matthew R. Smith, MD, PhD
|
|
|
Matthew R. Smith, MD, PhD, examines advances in managing risk of treatment-related and disease-related bone loss in patients with prostate cancer and in preventing fractures and other skeletal-related events.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the impact of androgen deprivation therapy on bone mass in patients with prostate cancer
- Identify risk factors for bone loss and describe bone mineral density–based criteria for osteopenia and osteoporosis
- Summarize clinical trial evidence supporting the efficacy of bisphosphonates in prevent androgen deprivation therapy–induced bone loss and identify common adverse events associated with bisphosphonates
- Summarize the clinical trial evidence supporting the use of zoledronic acid in reducing risk of skeletal-related events in patients with bone metastases from prostate cancer
- Explain the rationale for investigation of RANKL inhibition for treatment-related and disease-related bone loss in prostate cancer
Abstract
|
Bone Complications in Multiple Myeloma |
Module 3 of 4 |
- G. David Roodman, MD, PhD
|
|
|
G. David Roodman, MD, PhD, reviews the evolving understanding of the pathogenesis of bone destruction in multiple myeloma, current treatments to prevent skeletal complications, and emerging potential therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the pathologic and clinical features of multiple myeloma bone disease and explain how myeloma bone lesions differ from bone metastases in solid tumors
- Discuss the receptor activator of nuclear factor kappa B (RANK) and the RANK ligand/osteoprotegerin pathway and identify abnormalities of this pathway in multiple myeloma
- Discuss the efficacy and safety of bisphosphonates in patients with multiple myeloma
- Describe the rationale for RANK ligand inhibition in preventing skeletal complications in myeloma and discuss current clinical investigation of this treatment approach
- Discuss recent data relating to Dickkopf 1 (DKK1) in myeloma and explain the rationale for DKK1 inhibition as a possible treatment approach
Abstract
|
Beyond Breast and Prostate Cancer: Bone Health in Other Solid Tumors |
Module 4 of 4 |
|
|
|
Allan Lipton, MD, discusses current strategies to treat and prevent bone metastases in cancer patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the incidence of bone metastases and skeletal-related events in lung cancer, renal cancer, and thyroid cancer
- Cite currently available therapies for cancer patients with bone metastases
- Describe the investigational agents being evaluated for the treatment of patients with bone metastases
Abstract
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|